DIVA Laboratories, Ltd.

TPEX:4153 Stock Report

Market Cap: NT$1.8b

DIVA Laboratories Balance Sheet Health

Financial Health criteria checks 6/6

DIVA Laboratories has a total shareholder equity of NT$936.1M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.4B and NT$447.4M respectively. DIVA Laboratories's EBIT is NT$99.7M making its interest coverage ratio -17.2. It has cash and short-term investments of NT$475.6M.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ratio-17.2x
CashNT$475.64m
EquityNT$936.07m
Total liabilitiesNT$447.40m
Total assetsNT$1.38b

Recent financial health updates

No updates

Recent updates

Analysis Article Feb 28

Should You Be Impressed By DIVA Laboratories' (GTSM:4153) Returns on Capital?

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article Dec 27

DIVA Laboratories, Ltd. (GTSM:4153) Stock's On A Decline: Are Poor Fundamentals The Cause?

With its stock down 17% over the past three months, it is easy to disregard DIVA Laboratories (GTSM:4153). To decide if...
Analysis Article Nov 30

Is DIVA Laboratories (GTSM:4153) Likely To Turn Things Around?

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Financial Position Analysis

Short Term Liabilities: 4153's short term assets (NT$1.1B) exceed its short term liabilities (NT$446.3M).

Long Term Liabilities: 4153's short term assets (NT$1.1B) exceed its long term liabilities (NT$1.1M).


Debt to Equity History and Analysis

Debt Level: 4153 is debt free.

Reducing Debt: 4153 had no debt 5 years ago.

Debt Coverage: 4153 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4153 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 05:42
End of Day Share Price 2026/05/21 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DIVA Laboratories, Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hsiu Chi LinMasterlink Securities Investment Advisory